Initial situation

  • Biotechnology company with a patent protected first-in-class immunomodulatory drug in pipeline  –  new mode of action
  • Phase I successfully complemented
  • Active ingredient can be developed for different indications with indication-specific, galenic dosage forms
  • Company is looking for mid-size, indication-specific co-development partners to finance prove of concept studies
  • Phase III and launch will be done subsequent in cooperation with a global/regional partner and the current co-development partner

Tasks for SANEMUS

  • Identification of potential, indication-specific co-development partners
  • Contacting potential partners
  • Initiating licensing process and participation in contract negotiations